{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:21:31Z","timestamp":1779416491024,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2023AFD042"],"award-info":[{"award-number":["2023AFD042"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15832-7","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:49:08Z","timestamp":1776163748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Downregulation of THRB drives immune microenvironment suppression and poor outcomes, acting as a dual biomarker for clear cell renal cell carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Suzhen","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiegang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongshi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"12","key":"15832_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose TL, Kim WY. Renal Cell Carcinoma: A Review. JAMA. 2024;332(12):1001\u201310.","journal-title":"JAMA"},{"issue":"1","key":"15832_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40246-025-00764-3","volume":"19","author":"X Zhang","year":"2025","unstructured":"Zhang X, Yu Z, Yin L, Li Q, He S, Li H, et al. BAX-mediated ammonia-driven cell death: a novel prognostic and therapeutic target in clear cell renal cell carcinoma. Hum Genomics. 2025;19(1):57.","journal-title":"Hum Genomics"},{"issue":"19","key":"15832_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","volume":"388","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023;388(19):1767\u201378.","journal-title":"N Engl J Med"},{"issue":"7","key":"15832_CR4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","volume":"23","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888\u201398.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15832_CR5","doi-asserted-by":"publisher","first-page":"e97624","DOI":"10.1371\/journal.pone.0097624","volume":"9","author":"A Wojcicka","year":"2014","unstructured":"Wojcicka A, Piekielko-Witkowska A, Kedzierska H, Rybicka B, Poplawski P, Boguslawska J, et al. Epigenetic regulation of thyroid hormone receptor beta in renal cancer. PLoS ONE. 2014;9(5):e97624.","journal-title":"PLoS ONE"},{"issue":"27","key":"15832_CR6","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1038\/sj.onc.1205534","volume":"21","author":"JM Silva","year":"2002","unstructured":"Silva JM, Dom\u00ednguez G, Gonz\u00e1lez-Sancho JM, Garc\u00eda JM, Silva J, Garc\u00eda-Andrade C, et al. Expression of thyroid hormone receptor\/erbA genes is altered in human breast cancer. Oncogene. 2002;21(27):4307\u201316.","journal-title":"Oncogene"},{"issue":"1","key":"15832_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z","volume":"26","author":"KH Lin","year":"1999","unstructured":"Lin KH, Shieh HY, Chen SL, Hsu HC. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog. 1999;26(1):53\u201361.","journal-title":"Mol Carcinog"},{"issue":"3","key":"15832_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/105072501750159750","volume":"11","author":"JD Safer","year":"2001","unstructured":"Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid. 2001;11(3):281\u201391.","journal-title":"Thyroid"},{"issue":"11","key":"15832_CR9","first-page":"5572","volume":"86","author":"S Ando","year":"2001","unstructured":"Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab. 2001;86(11):5572\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"15832_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1210\/jcem.87.3.8296","volume":"87","author":"M Puzianowska-Kuznicka","year":"2002","unstructured":"Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab. 2002;87(3):1120\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"15832_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/0008-5472.CAN-08-2198","volume":"69","author":"O Mart\u00ednez-Iglesias","year":"2009","unstructured":"Mart\u00ednez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res. 2009;69(2):501\u20139.","journal-title":"Cancer Res"},{"issue":"W1","key":"15832_CR12","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"15832_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284\u20137.","journal-title":"Omics"},{"key":"15832_CR14","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"5","key":"15832_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"25","key":"15832_CR16","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"issue":"9","key":"15832_CR17","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.","journal-title":"PLoS ONE"},{"issue":"6","key":"15832_CR18","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","volume":"10","author":"Y Lv","year":"2023","unstructured":"Lv Y, Ma X, Ma Y, Du Y, Feng J. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). Genes Dis. 2023;10(6):2366\u201382.","journal-title":"Genes Dis"},{"key":"15832_CR19","doi-asserted-by":"publisher","first-page":"175097","DOI":"10.1016\/j.ejphar.2022.175097","volume":"928","author":"J Wu","year":"2022","unstructured":"Wu J, Wang Y. Role of TNFSF9 bidirectional signal transduction in antitumor immunotherapy. Eur J Pharmacol. 2022;928:175097.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"15832_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10142-023-00977-6","volume":"23","author":"F Kong","year":"2023","unstructured":"Kong F, Ye Q, Xiong Y. Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer. Funct Integr Genomics. 2023;23(1):48.","journal-title":"Funct Integr Genomics"},{"issue":"4","key":"15832_CR21","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1002\/imt2.147","volume":"2","author":"J Meng","year":"2023","unstructured":"Meng J, Jiang A, Lu X, Gu D, Ge Q, Bai S, et al. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy. Imeta. 2023;2(4):e147.","journal-title":"Imeta"},{"key":"15832_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2017.03.014","volume":"615","author":"H Xian","year":"2017","unstructured":"Xian H, Wang F, Teng W, Yang D, Zhang M. Thyroid hormone induce a p53-dependent DNA damage through PI3K\/Akt activation in sperm. Gene. 2017;615:1\u20137.","journal-title":"Gene"},{"issue":"5","key":"15832_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00281-016-0566-0","volume":"38","author":"H Morita","year":"2016","unstructured":"Morita H, Saito H, Matsumoto K, Nakae S. Regulatory roles of mast cells in immune responses. Semin Immunopathol. 2016;38(5):623\u20139.","journal-title":"Semin Immunopathol"},{"issue":"4","key":"15832_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4049\/jimmunol.1801228","volume":"203","author":"D Haydar","year":"2019","unstructured":"Haydar D, Cory TJ, Birket SE, Murphy BS, Pennypacker KR, Sinai AP, et al. Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-\u03baB Signaling Pathways. J Immunol. 2019;203(4):1021\u201330.","journal-title":"J Immunol"},{"issue":"12","key":"15832_CR25","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.4049\/jimmunol.1500200","volume":"194","author":"JP Nance","year":"2015","unstructured":"Nance JP, B\u00e9langer S, Johnston RJ, Takemori T, Crotty S. Cutting edge: T follicular helper cell differentiation is defective in the absence of Bcl6 BTB repressor domain function. J Immunol. 2015;194(12):5599\u2013603.","journal-title":"J Immunol"},{"issue":"4","key":"15832_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.immuni.2017.03.015","volume":"46","author":"JE Konkel","year":"2017","unstructured":"Konkel JE, Zhang D, Zanvit P, Chia C, Zangarle-Murray T, Jin W, et al. Transforming Growth Factor-\u03b2 Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses. Immunity. 2017;46(4):660\u201374.","journal-title":"Immunity"},{"issue":"10","key":"15832_CR27","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1172\/JCI76179","volume":"124","author":"MJ McCarron","year":"2014","unstructured":"McCarron MJ, Marie JC. TGF-\u03b2 prevents T follicular helper cell accumulation and B cell autoreactivity. J Clin Invest. 2014;124(10):4375\u201386.","journal-title":"J Clin Invest"},{"key":"15832_CR28","doi-asserted-by":"publisher","first-page":"150738","DOI":"10.1016\/j.bbrc.2024.150738","volume":"734","author":"M Liu","year":"2024","unstructured":"Liu M, Fu X, Yi Q, Xu E, Dong L. Impaired mitochondrial oxidative phosphorylation induces CD8(+) T cell exhaustion. Biochem Biophys Res Commun. 2024;734:150738.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"15832_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12944-023-01807-1","volume":"22","author":"X Qiao","year":"2023","unstructured":"Qiao X, Hu Z, Xiong F, Yang Y, Peng C, Wang D, et al. Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids Health Dis. 2023;22(1):45.","journal-title":"Lipids Health Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15832-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:22:14Z","timestamp":1779412934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15832-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15832"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15832-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"666"}}